title: Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH analog.
abstract: OBJECTIVE
  This study was undertaken to compare the clinical and endocrinological results of two kinds of treatment on adolescents with polycystic ovarian disease (PCOD).
  
  
  METHODS
  Forty-five adolescents with PCOD were randomly allocated into two groups, treated either with ethinylestradiol (EE)/cyproterone acetate (group A) or the GnRH analog D-Tr-6-LHRH (group B).
  
  
  RESULTS
  No significant changes were detected on the body mass index and waist-hip circumference. A significant improvement of hirsutism was noticed in both groups of patients. A normal menstrual period was recorded in group A adolescents while all group B patients became amenorrheic. A favorable decrease of ovarian volume was detected in both groups. LH/FSH ratio and delta 4-androstenedione serum levels were found significantly reduced in both groups in comparison to pre-treatment levels. The comparison between the two groups, after 6 months, showed significantly lower values of LH/FSH ratio in group B cases.
  
  
  CONCLUSIONS
  Both forms of treatment are safe and effective to a various degree for the management of PCOD adolescents.
authors.affiliation: 1st Department of Obstetrics and Gynecology, Alexandra Hospital, University of Athens Greece.
authors.forename: G
authors.initials: G
authors.lastname: Creatsas
authors.forename: E
authors.initials: E
authors.lastname: Hassan
authors.forename: E
authors.initials: E
authors.lastname: Deligeoroglou
authors.forename: G
authors.initials: G
authors.lastname: Tolis
authors.forename: D
authors.initials: D
authors.lastname: Aravantinos
mesh_terms: D000293:Adolescent; D000735:Androstenedione / Q000097:blood; D017373:Cyproterone Acetate / Q000627:therapeutic use*; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000097:blood; D019314:Dehydroepiandrosterone Sulfate; D003692:Delayed-Action Preparations; D015232:Dinoprostone / Q000097:blood; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D003692:Delayed-Action Preparations; D012738:Sex Hormone-Binding Globulin; D017329:Triptorelin Pamoate; D013739:Testosterone; D000735:Androstenedione; D004997:Ethinyl Estradiol; D003687:Dehydroepiandrosterone; D017373:Cyproterone Acetate; D019314:Dehydroepiandrosterone Sulfate; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D015232:Dinoprostone